The potential of catestatin in the diagnostics of cardiovascular diseases: current data and perspectives

Pankova O.

Kharkiv medical academy of postgraduation education

Cardiovascular diseases are not only the most common non-communicable diseases, but also occupy the leading place in the structure of total mortality in the world population. Among the wide range of pathogenetic mechanisms of the above-mentioned pathology, an increase in the activity of the sympathetic nervous system should be marked, given that catestatin, known primarily for its ability to inhibit hyperactivation of the sympathetic nervous system, deserves special attention. This article considers the issue of the diagnostic potential of catestatin in the management of cardiovascular pathology. The literature analysis made it possible to determine the dynamics of catestatin levels during the development of coronary heart disease and heart failure. The established correlations of catestatin with other cardiovascular biomarkers, such as NT-proBNP, sST2, hscTnI, allow us to note its potential place in the diagnosis of cardiovascular pathology. The results of numerous clinical studies demonstrated the correlation between catestatin levels and the development of complications, including the level of mortality, which allows considering catestatin as a predictor of the development of complications of cardiovascular diseases. Therefore, the prognostic value of catestatin levels in patients with coronary heart disease and heart failure allows it to be considered a marker of these diseases.

Key words: catestatin, chromogranin A, cardiovascular diseases, coronary heart disease, heart failure

Download.PDF (ukr)

Для цитування:

  1. Панкова, О.А. Потенціал катестатину у діагностиці серцево-судинних захворювань: сучасні дані та перспективи // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2022. – № 2. – С. 43-48. doi: 15407/internalmed2022.02.043
  2. Pankova O. [The potential of catestatin in the diagnostics of cardiovascular diseases: current data and perspectives]. Shidnoevr. z. vnutr. simejnoi med. 2022;2:43-48. Ukrainian. doi: 10.15407/internalmed2022.02.043


  1. Malakar A, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. Journal of Cellular Physiology. 2019;234(10):16812-16823.
  2. Bozic J, Kumric M, Ticinovic Kurir T, Urlic H, Martinovic D, Vilovic M, Tomasovic Mrcela N, Borovac J. Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective. Biomedicines. 2021;9(12):1757.
  3. Pankova OA. Katestatyn yak rehulyator aktyvnosti sympatychnoyi nervovoyi systemy ta joho vplyv na rozvytok i prohresuvannya hipertonichnoyi xvoroby ta cukrovoho diabetu 2 typu. Problemy bezperervnoyi medychnoyi osvity ta nauky. 2021;2 (42):49–54. doi: 10.31071/ promedosvity2021.02.049. Ukrainian
  4. Bourebaba Y, Mularczyk M, Marycz K, Bourebaba L. Catestatin peptide of chromogranin A as a potential new target for several risk factors management in the course of metabolic syndrome. Biomedicine & Pharmacotherapy. 2021;134:111113.
  5. Pankova OA. Rol” katestatynu u rehulyaciyi metabolichnyx rozhlyadiv. Ohlyad // Medychna nauka Ukrayiny. 2022;18(2):69–78. doi: 10.32345/2664-4738.2.2022.09. Ukrainian
  6. Watanabe T. The Emerging Roles of Chromogranins and Derived Polypeptides in Atherosclerosis, Diabetes, and Coronary Heart Disease. International Journal of Molecular Sciences. 2021;22(11):6118.
  7. Zalewska E, Kmieć P, Sworczak K. Role of Catestatin in the Cardiovascular System and Metabolic Disorders. Frontiers in Cardiovascular Medicine. 2022;9:.
  8. Mahata S, O’Connor D, Mahata M, Yoo S, Taupenot L, Wu H, Gill B, Parmer R. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.. Journal of Clinical Investigation. 1997;100(6):1623-1633.
  9. Tsigelny I, Mahata S, Taupenot L, Preece N, Mahata M, Khan I, Parmer R, O’Connor D. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a β-strand/loop/β-strand structure secured by hydrophobic interactions and predictive of activity. Regulatory Peptides. 1998;77(1-3):43-53.
  10. Kojima M, Ozawa N, Mori Y, Takahashi Y, Watanabe-Kominato K, Shirai R, Watanabe R, Sato K, Matsuyama T, Ishibashi-Ueda H, Koba S, Kobayashi Y, Hirano T, Watanabe T. Catestatin Prevents Macrophage-Driven Atherosclerosis but Not Arterial Injury–Induced Neointimal Hyperplasia. Thrombosis and Haemostasis. 2018;118(01):182-194.
  11. Chen Y, Wang X, Yang C, Su X, Yang W, Dai Y, Han H, Jiang J, Lu L, Wang H, Chen Q, Jin W. Decreased circulating catestatin levels are associated with coronary artery disease: The emerging anti-inflammatory role. Atherosclerosis. 2019;281:78-88.
  12. Zhu D, Xie H, Wang X, Liang Y, Yu H, Gao W. Catestatin-A Novel Predictor of Left Ventricular Remodeling After Acute Myocardial Infarction. Scientific Reports. 2017;7(1):.
  13. Zhu D, Xie H, Wang X, Liang Y, Yu H, Gao W. Correlation of Plasma Catestatin Level and the Prognosis of Patients with Acute Myocardial Infarction. PLOS ONE. 2015;10(4):e0122993.
  14. Wang X, Xu S, Liang Y, Zhu D, Mi L, Wang G, Gao W. Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction. Biomarkers. 2011;16(4):372-377.
  15. Pei Z, Ma D, Ji L, Zhang J, Su J, Xue W, Chen X, Wang W. Usefulness of catestatin to predict malignant arrhythmia in patients with acute myocardial infarction. Peptides. 2014;55:131-135.
  16. Liu L, Ding W, Zhao F, Shi L, Pang Y, Tang C. Plasma levels and potential roles of catestatin in patients with coronary heart disease. Scandinavian Cardiovascular Journal. 2013;47(4):217-224.
  17. Zhi-qiang P, Zhi-qiang P. Prognostic value of circulating catestatin levels for in-hospital heart failure in patients with acute myocardial infarction. Heart. 2012;98(Suppl 2):E171.2-E172.
  18. Meng L, Wang J, Ding W, Han P, Yang Y, Qi L, Zhang B, Ding W. Plasma catestatin level in patients with acute myocardial infarction and its correlation with ventricular remodelling. Heart. 2012;98(Suppl 2):E170.3-E170.
  19. Xu W, Yu H, Wu H, Li S, Chen B, Gao W. Plasma Catestatin in Patients with Acute Coronary Syndrome. Cardiology. 2016;136(3):164-169.
  20. Zhu D, Wang F, Yu H, Mi L, Gao W. Catestatin is useful in detecting patients with stage B heart failure. Biomarkers. 2011;16(8):691-697.
  21. Liu L, Ding W, Li R, Ye X, Zhao J, Jiang J, Meng L, Wang J, Chu S, Han X, Peng F. Plasma levels and diagnostic value of catestatin in patients with heart failure. Peptides. 2013;46:20-25.
  22. Höglund K, Häggström J, Höglund O, Stridsberg M, Tidholm A, Ljungvall I. The chromogranin A-derived peptides catestatin and vasostatin in dogs with myxomatous mitral valve disease. Acta Veterinaria Scandinavica. 2020;62(1):.
  23. Borovac J, Glavas D, Susilovic Grabovac Z, Supe Domic D, D’Amario D, Bozic J. Catestatin in Acutely Decompensated Heart Failure Patients: Insights from the CATSTAT-HF Study. Journal of Clinical Medicine. 2019;8(8):1132.
  24. Wołowiec Ł, Rogowicz D, Banach J, Gilewski W, Sinkiewicz W, Grześk G. Catestatin as a New Prognostic Marker in Stable Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up. Disease Markers. 2020;2020:1-10.
  25. Borovac J, Glavas D, Susilovic Grabovac Z, Supe Domic D, Stanisic L, D’Amario D, Kwok C, Bozic J. Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT‐HF study. ESC Heart Failure. 2020;7(5):2818-2828.
  26. Izci S, Acar E, Inanir M. Plasma catestatin level predicts sPESI score and mortality in acute pulmonary embolism. Archives of Medical Science – Atherosclerotic Diseases. 2020;5(1):49-56.
  27. Peng F, Chu S, Ding W, Liu L, Zhao J, Cui X, Li R, Wang J. The predictive value of plasma catestatin for all-cause and cardiac deaths in chronic heart failure patients. Peptides. 2016;86:112-117.
  28. Sun H, Xian W, Geng L, Li E, Peng Z, Tian J. Increased plasma level of catestatin might be associated with poor prognosis in hemodialysis patients. International Urology and Nephrology. 2017;49(6):1063-1069.
  29. Luketin M, Mizdrak M, Boric-Skaro D, Martinovic D, Tokic D, Vilovic M, Supe-Domic D, Ticinovic Kurir T, Bozic J. Plasma Catestatin Levels and Advanced Glycation End Products in Patients on Hemodialysis. Biomolecules. 2021;11(3):456.
  30. Wang D, Liu T, Shi S, Li R, Shan Y, Huang Y, Hu D, Huang C. Chronic Administration of Catestatin Improves Autonomic Function and Exerts Cardioprotective Effects in Myocardial Infarction Rats. Journal of Cardiovascular Pharmacology and Therapeutics. 2016;21(6):526-535.
  31. Chen H, Liu D, Ge L, Wang T, Ma Z, Han Y, Duan Y, Xu X, Liu W, Yuan J, Liu J, Li R, Du R. Catestatin prevents endothelial inflammation and promotes thrombus resolution in acute pulmonary embolism in mice. Bioscience Reports. 2019;39(11):.
  32. Özalp M, Yaman H, Demir Ö, Aytekin Garip S, Aran T, Osmanağaoğlu M. The role of maternal serum catestatin in the evaluation of preeclampsia and fetal cardiac functions. Journal of Turkish Society of Obstetric and Gynecology. 2021;18(4):272-278.
  33. Bralewska M, Biesiada L, Grzesiak M, Rybak-Krzyszkowska M, Huras H, Gach A, Pietrucha T, Sakowicz A. Chromogranin A demonstrates higher expression in preeclamptic placentas than in normal pregnancy. BMC Pregnancy and Childbirth. 2021;21(1):.
  34. Tüten N, Güralp O, Gök K, Hamzaoglu K, Oner Y, Makul M, Bulut H, Irmak K, Tüten A, Malik E. Serum catestatin level is increased in women with preeclampsia. Journal of Obstetrics and Gynaecology. 2021;42(1):55-60.